Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
ID: 337330Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) to support innovative research aimed at addressing significant biomedical challenges through bioengineering solutions. This funding opportunity encourages applications that explore novel scientific ideas or technologies, focusing on enhancing quality, efficacy, operability, and accessibility in basic, pre-clinical, and clinical research, without the need for extensive preliminary data. The grant provides a budget of up to $275,000 over a two-year period, with eligibility extending to a wide range of applicants, including higher education institutions, nonprofits, for-profits, and foreign entities. Interested applicants should adhere to NIH policies and guidelines, with a submission deadline of January 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-090.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed). This funding opportunity aims to encourage innovative research exploring new bioengineering solutions for significant biomedical challenges, promoting advancements in quality, efficacy, operability, and accessibility within basic, pre-clinical, and clinical research. The grant allows applications focusing on novel scientific ideas or technologies without requiring extensive preliminary data, with a budget capped at $275,000 over two years. Eligible applicants include higher education institutions, nonprofits, for-profits, and foreign entities, among others. Applications must adhere to NIH policies and guidelines, and compliance with submission requirements is strictly enforced. The review process prioritizes originality, significance, and the feasibility of proposed research objectives, emphasizing cross-disciplinary collaboration between bioengineering and biomedical sciences. The initiative reflects NIH's commitment to enhancing health outcomes through innovative engineering applications in medical research.
    Similar Opportunities
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 funding mechanism, aimed at fostering innovative projects that address significant biomedical challenges. This funding opportunity encourages applications that explore new capabilities or improvements in biomedical research, clinical care delivery, and accessibility, with a focus on groundbreaking engineering research and collaboration across diverse scientific disciplines. Eligible applicants include higher education institutions, nonprofits, and small businesses, with a budget cap of $275,000 over two years, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-091.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Bioengineering Research Grants (BRG), aimed at fostering multidisciplinary collaborations to address significant biomedical challenges. This funding opportunity encourages innovative research that integrates life and physical sciences to develop tools, methods, and technologies that can enhance healthcare delivery and medical practices. Eligible applicants include a diverse range of institutions, such as historically black colleges, tribal colleges, and community-based organizations, with projects allowed to span up to five years under the R01 grant mechanism. Interested parties should submit their applications electronically by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Bioengineering Research Grants (BRG) to encourage multidisciplinary collaborations that address significant biomedical challenges through innovative technologies. This funding opportunity aims to integrate life and physical sciences to accelerate the adoption of promising tools and methods in clinical or translational science, with a focus on projects that may involve clinical trials assessing functionality or performance in real-world settings. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and foreign entities, with no cost-sharing requirement, and applications are due by September 7, 2025. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-22-243.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21), aimed at supporting innovative early-stage research projects in the biomedical, behavioral, and clinical fields. This funding opportunity is specifically designed for basic experimental studies involving human participants, with a focus on developing novel techniques or methodologies that can significantly advance scientific understanding. Eligible applicants, including small businesses and various institutions, can receive funding of up to $275,000 over a two-year period, with applications accepted on a rolling basis until the close date of January 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PA-20-196.html.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)" aimed at enhancing biomedical engineering education through innovative team-based design courses. This initiative seeks to support educational programs that prepare undergraduate students in biomedical engineering/bioengineering fields to meet national biomedical needs, with a focus on promoting health equity and universal design. Institutions can apply for grants of up to $40,000 per year for projects lasting up to five years, with a submission deadline of January 30, 2025. Interested applicants should ensure compliance with eligibility criteria and submit detailed proposals that include innovative educational plans and collaborations with relevant disciplines; for further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation" (R21 Clinical Trial Optional). This initiative aims to support research that addresses ethical questions throughout the design, testing, and implementation phases of bionic and robotic devices, focusing on issues such as autonomy, informed consent, and equitable access to technology. A total of $2 million is available to fund 4-5 awards, with each project budget capped at $275,000 over two years. Interested applicants must submit their proposals by January 26, 2024, and can find additional details and guidelines at the NIH grants website or by contacting grantsinfo@nih.gov.